Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $9.45.

Several research firms have recently issued reports on HCAT. Canaccord Genuity Group lowered their price objective on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company lowered their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a research report on Wednesday, January 8th. Citigroup decreased their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Finally, Stephens reissued an “equal weight” rating and set a $7.00 target price on shares of Health Catalyst in a research report on Thursday, February 27th.

Insiders Place Their Bets

In related news, CFO Jason Alger sold 19,599 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the transaction, the chief financial officer now directly owns 86,712 shares in the company, valued at $721,443.84. This trade represents a 18.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Linda Llewelyn sold 6,441 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the transaction, the insider now owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,110 shares of company stock worth $596,993. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of large investors have recently modified their holdings of the company. Mackenzie Financial Corp bought a new position in shares of Health Catalyst in the 4th quarter worth $248,000. PharVision Advisers LLC bought a new position in Health Catalyst during the 4th quarter valued at $185,000. Two Sigma Advisers LP lifted its stake in Health Catalyst by 72.7% during the 4th quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock valued at $210,000 after acquiring an additional 12,500 shares in the last quarter. Two Sigma Investments LP bought a new position in Health Catalyst during the 4th quarter valued at $496,000. Finally, ProShare Advisors LLC lifted its stake in Health Catalyst by 52.7% during the 4th quarter. ProShare Advisors LLC now owns 16,854 shares of the company’s stock valued at $119,000 after acquiring an additional 5,815 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Stock Performance

Health Catalyst stock opened at $4.52 on Wednesday. The business has a 50 day moving average of $5.89 and a 200-day moving average of $7.21. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a market capitalization of $275.03 million, a P/E ratio of -3.35 and a beta of 1.34.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.